Advertisement
"We are confident that the experienced sales professionals ofEndotherapeutics will successfully launch ActiPatch in the Australian market.Endotherapeutics' team has many decades of experience in the medical devicesmarket and their people come from well known established medical devicescompanies," said Andrew Whelan, President of BioElectronics Corporation.
Advertisement
Ivan Srejber, Managing Director of Endotherapeutics Party Limited, said"We have extensive experience in launching products and establishingsignificant market share for previously unknown products. We are very excitedabout the market potential for ActiPatch in Australia and look forward to amutually beneficial business partnership with BioElectronics Corporation."
About Endotherapeutics Party Limited:
Founded in 1998, Endotherapeutics has provided medical technologies forthe health care specialist throughout Australia. Companies represented byEndotherapeutics are leaders in their specific market segments. To learn moreabout Endotherapeutics Party Limited please visithttp://www.endotherapeutics.com.au.
About BioElectronics:
BioElectronics Corporation is the maker of ActiPatch. ActiPatch is adrug-free anti-inflammatory patch with an embedded battery operated microchipthat delivers weeks of continuous pulsed therapy for less than a dollar a day.The unique ActiPatch delivery system, using patented technology, provides acost-effective, patient friendly method to reduce soft tissue pain andswelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to futuregrowth and earnings opportunities. Such statements are based upon certainassumptions and assessments made by management of both companies in light ofcurrent conditions, expected future developments and other factors it believesto be appropriate. Actual results may differ as a result of factors overwhich the companies have no control.
SOURCE BioElectronics Corporation
